PROGRAMMED CELL DEATH IN LYMPHOCYTES
PROGRAMMED CELL DEATH IN LYMPHOCYTES
批准号:
3796542
负责人:
P A HENKART
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
CD3 molecule DNA DNA repair RNA directed DNA polymerase affinity chromatography antibody receptor aprotinin biological signal transduction calpain cellular immunity cytolysins cytotoxic T lymphocyte cytotoxicity exocytosis fluorescent dye /probe fluorimetry gel filtration chromatography gene expression granule helper T lymphocyte interleukin 2 interleukin 4 killer cells laboratory rat messenger RNA monoclonal antibody natural killer cells peptidases polymerase chain reaction pore forming protein protease inhibitor protein structure function proteoglycan secretion tissue /cell culture
中文摘要
为了验证淋巴细胞程序性死亡的假设
涉及内源性蛋白酶的激活,我们已经测试了
几种半胱氨酸蛋白酶抑制剂,以阻止TcR诱导的死亡,
CD 4 + T细胞杂交瘤2B 4。 两个化学性质不同的家族
钙蛋白酶和组织蛋白酶的抑制剂,E-64和亮抑酶肽家族,
通过台盼蓝测定发现,
在固定化α-CD 3上过夜培养后碘化丙啶摄取
或α-TcR抗体。 流式显微荧光法测定DNA断裂
也被封锁了。 这些药物通过增强TcR诱导的IL-2分泌,
多达9倍,表明它们不通过干扰
信号转导 淋巴细胞中的其他程序性细胞死亡系统
测试的是类固醇诱导的CD 4 + CD 8+胸腺细胞死亡,
和CH 31 B细胞系,其
这些抑制剂不影响mIgM诱导的死亡。 我们还
发现短期培养的淋巴细胞可以进行细胞程序化,
TcR交联后死亡。 在激活纯化的静息后,
小鼠淋巴结T细胞(或PNA+胸腺细胞)通过固定化α-CD 3或
α-TcR抗体,连续分裂的细胞被维持在
IL 2持续数天至数周的时间。 当重新暴露于表面结合的
针对TcR或CD 3的抗体,这些细胞被发现经历了
细胞分裂和线粒体代谢减少,伴有
大量的细胞死亡 当纯化的CD 4+和CD 8+细胞群体
以这种方式培养,细胞死亡效应主要见于
CD 4群体,在CD 8群体中的所有缓解中的影响更温和
人口 在CD 4+细胞中,可以清楚地看到DNA断裂,
当通过流动显微荧光测定法分析时伴随细胞死亡。 这种效果
被环孢菌素阻断,与脾巨噬细胞共培养,或
半胱氨酸蛋白酶抑制剂。
英文摘要
In order to test the hypothesis programmed cell death in lymphocytes
involves activation of an endogenous protease, we have tested the ability
of several cysteine protease inhibitors to block the TcR-induced death of
the CD4+ T cell hybridoma 2B4. Two chemically distinct families of
inhibitors of calpains and cathepsins, the E-64 and leupeptin families,
were found to rescue 2B4 cells from death measured by trypan blue or
propidium iodide uptake after overnight culture on immobilized alpha-CD3
or alpha-TcR antibodies. DNA breakdown measured by flow microfluorimetry
was also blocked. These drugs enhanced the TcR-induced IL-2 secretion by
as much as 9-fold, showing that they do not act by interfering with
signal transduction. Other programmed cell death systems in lymphocytes
tested were the steroid-induced death of CD4+CD8+ thymocytes, which was
blocked by leupeptin family inhibitors, and the CH31 B cell line, whose
mIgM-induced death was unaffected by these inhibitors. We have also
found that short-term-cultured lymphocytes can undergo programmed cell
death after TcR cross-linking. After activation of purified resting
mouse lymph node T cells (or PNA+ thymocytes) by immobilized alpha-CD3 or
alpha-TcR antibodies, continuously dividing cells were be maintained in
IL2 for periods of days to weeks. When re-exposed to surface-bound
antibodies against TcR or CD3, these cells were found to undergo a
decrease in cell division and mitochondrial metabolism, accompanied by
substantial cell death. When purified populations of CD4+ and CD8+ cells
were cultured this way, the cell death effect was principally seen in the
CD4 population, with more modest effects in all responses in the CD8
population. In the CD4+ cells DNA breakdown was clearly seen to
accompany cell death when analyzed by flow microfluorimetry. This effect
was blocked by cyclosporin, co-culture with splenic macrophages, or
cysteine protease inhibitors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
APOPTOTIC DEATH IN T LYMPHOCYTES
-
批准号:6100954
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:P A HENKART
-
依托单位:
TARGET CELL DAMAGE BY IMMUNE MECHANISMS
-
批准号:3796537
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:P A HENKART
-
依托单位:
PROGRAMMED CELL DEATH IN LYMPHOCYTES
-
批准号:3774389
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:P A HENKART
-
依托单位:
TARGET CELL DAMAGE BY IMMUNE MECHANISMS
-
批准号:6161048
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:P A HENKART
-
依托单位:
PROGRAMMED CELL DEATH IN LYMPHOCYTES
-
批准号:3752092
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:P A HENKART
-
依托单位:
APOPTOTIC DEATH IN T LYMPHOCYTES
-
批准号:6161054
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:P A HENKART
-
依托单位:
TARGET CELL DAMAGE BY IMMUNE MECHANISMS
-
批准号:3813453
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:P A HENKART
-
依托单位:
TARGET CELL DAMAGE BY IMMUNE MECHANISMS
-
批准号:3916398
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:P A HENKART
-
依托单位:
STRUCTURE AND FUNCTION OF CYTOTOXIC AND HELPER T LYMPHOCYTE GRANULES
-
批准号:3916408
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:P A HENKART
-
依托单位:
MEMBRANE DAMAGE BY IMMUNE MECHANISMS
-
批准号:3962935
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:P A HENKART
-
依托单位:
MEMBRANE DAMAGE BY IMMUNE MECHANISMS
-
批准号:4691749
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:P A HENKART
-
依托单位:
PROGRAMMED CELL DEATH IN LYMPHOCYTES
-
批准号:5201007
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:P A HENKART
-
依托单位:
TARGET CELL DAMAGE BY IMMUNE MECHANISMS
-
批准号:5201003
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:P A HENKART
-
依托单位:
STRUCTURE AND FUNCTION OF CYTOTOXIC T LYMPHOCYTE GRANULES
-
批准号:3939239
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:P A HENKART
-
依托单位:
TARGET CELL DAMAGE BY IMMUNE MECHANISMS
-
批准号:6100948
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:P A HENKART
-
依托单位:
TARGET CELL DAMAGE BY IMMUNE MECHANISMS
-
批准号:3774385
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:P A HENKART
-
依托单位:
STRUCTURE AND FUNCTION OF CYTOTOXIC T LYMPHOCYTE GRANULES
-
批准号:4691768
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:P A HENKART
-
依托单位:
TARGET CELL DAMAGE BY IMMUNE MECHANISMS
-
批准号:3808591
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:P A HENKART
-
依托单位:
STRUCTURE AND FUNCTION OF CYTOTOXIC T LYMPHOCYTE GRANULES
-
批准号:3962951
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:P A HENKART
-
依托单位:
TARGET CELL DAMAGE BY IMMUNE MECHANISMS
-
批准号:3752088
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:P A HENKART
-
依托单位:
国内基金
海外基金
登录
查看更多内容
自供能传感阵列同步量化游离DNA与PSA实现前列腺癌的诊断和预后判断
-
批准号:JCZRLH202601177
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
二氢杨梅素通过线粒体代谢重编程抑制DNA同源重组修复逆转口腔癌细胞放疗抵抗的机制研究
-
批准号:2026JJ80500
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:阳帆
-
依托单位:
乳酸通过ESM1-Akt-MDM2-p53通路调控卵巢癌DNA损伤和抗肿瘤免疫应答的分子机制研究
-
批准号:2026JJ81975
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:肖娇
-
依托单位:
淫羊藿苷通过TET2介导DNA去甲基化调控Hippo-YAP/TAZ通路逆转绝经后骨质疏松症成血管-成骨耦联失衡的机制研究
-
批准号:2026JJ82371
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:王哲享
-
依托单位:
CDC45通过调控DNA复制应激促进肝癌发生发展的机制
-
批准号:2026JJ82714
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:赵志坚
-
依托单位:
PCV2茎环结构DNA激活cGAS-STING通路诱导的天然免疫应答的作用研究
-
批准号:2026JJ50413
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:王东亮
-
依托单位:
机械力响应型DNA探针用于肿瘤微环境细胞力学可视化与药物筛选研究
-
批准号:2026JJ60135
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:杨思慧
-
依托单位:
基于孕妇外周血游离DNA靶向捕获测序筛查胎儿隐性单基因病的探索研究
-
批准号:JCZRLH202600067
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
WSTF/SNF2H 介导的 DNA 损伤在 DPSCs 衰老中的机制研究
-
批准号:ZCLQN26H1401
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:虞其豪
-
依托单位:
孕期多环芳烃暴露与DNA甲基化改变对子代神经发育影响的出生队列研究
-
批准号:2026JJ81844
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:吕玲双
-
依托单位: